Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes

J Diabetes Complications. 2019 Jun;33(6):462-464. doi: 10.1016/j.jdiacomp.2019.03.003. Epub 2019 Mar 21.

Authors

Silvio E Inzucchi¹, Vivian Fonseca²

Affiliations

¹ Section of Endocrinology, Yale School of Medicine, New Haven, CT, United States of America.
² Tulane University, United States of America. Electronic address: vfonseca@tulane.edu.

PMID: 31003925
DOI: 10.1016/j.jdiacomp.2019.03.003

No abstract available

Publication types

Editorial

MeSH terms

Contraindications, Drug
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology
Diabetic Nephropathies / drug therapy
Diabetic Nephropathies / epidemiology
Drug Administration Schedule
Drug Therapy, Combination / classification
Drug Therapy, Combination / methods
Drug Therapy, Combination / trends
Endocrinology / methods
Endocrinology / trends*
Evidence-Based Practice / methods
Evidence-Based Practice / trends
Glycated Hemoglobin / analysis
Glycated Hemoglobin / drug effects
Humans
Hypoglycemic Agents / administration & dosage*
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / classification*
Metformin / administration & dosage*
Metformin / adverse effects
Precision Medicine / methods
Precision Medicine / trends*
Renal Insufficiency, Chronic / complications
Renal Insufficiency, Chronic / drug therapy

Substances

Glycated Hemoglobin A
Hypoglycemic Agents
Metformin